Tuesday, October 7

(The presenters of gray titles did not allow the online appearance of their lectures )

22. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-12.00 – Tuesday, October 7

Chair Persons: R.M. Hoffman, F.E. Ahmed, P. Kumar

Cell cycle decoy with Salmonella typhimurium A1-R to convert tumors from chemo-resistant to sensitive. S. Yano, M. Zhao, T. Fujiwara, R.M. Hoffman (San Diego, CA, USA; Okayama, Japan) (30’)
Desmoglein 3 acts as a mechanosensor in response to environmental mechanical property. H. Wan, F. Kenny, J. Connelly (London, UK) (20’)
Redox regulation of the cell cycle in health and disease. P.C.Goswami (Iowa City, IA, USA) (30’)
A new target of Ras-signaling pathway that promotes angiogenesis in aggressive breast cancer. B.K. Ray, A. Ray (Columbia, MO, USA) (30’)
RT-QPCR and its application to medicine and molecular biology. F.E. Ahmed, N.C. Ahmed (Greenville, NC, USA) (30’)
A physiological in vivo model for neuroectodermal child-cancer. I.Hultman, L. Ährlund-Richter (Stockholm, Sweden) (30’)
The expression and the role of glutamate receptors in cancer. A. Stepulac (Lublin, Poland) (30’)
Wnt signaling as a target of anti-breast cancer drug discovery. V.L. Katanaev (Lausanne, Switzerland) (25′)

23. HOX GENES IN CANCER
Special Symposium Organized by C. Aukim-Hastie and R. Morgan

ROOM A, 13.00-16.20 – Tuesday, October 7

Chair Persons: R. Morgan, C. Aukim-Hastie

Introduction: R. Morgan(10’)
HOX transcription factors are potential targets and markers in malignant mesothelioma. R. Morgan, S. Gray, C. Gillett, Z. Tabi, F. Launchbury, J. Spicer, K. Harrington, H.S. Pandha (Guilford; London; Cardiff, UK) (20’)
HOX genes in head and neck squamous cell carcinoma (HNSCC). K.D. Hunter (Sheffield, UK) (20’)
Targeting the HOX transcription factors and CD71 in multiple myeloma. T.R. Daniels, I.I. Neacato, J.A. Rodríguez, H.S. Pandha, R. Morgan, M.L. Penichet (Los Angeles, CA, USA; Guildford, UK) (20’)
Giving birth to blood stem cells, in vitro: HOXB4 promotes hematopoiesis during pluripotent stem cell differentiation by increasing the pool of hemogenic endothelium cells. N. Teichweyde, L.Kasperidus, S. Skibbe, P. Horn, H. Klump (Essen, Germany) (20’)
Investigating the role of homeobox genes in breast cancer stem cell function. M. Shah, R. Emes,A. Grabowska, C. Allegrucci (Loughborough; Nottingham, UK) (20 ‘)
Candidate drug screening in HOX-related models of AML. C.L. Burt, L.M.J. Kettyle, N.M. Mulgrew, J.M. Ramsey, G.J. Dickson, A. Thompson (Belfast; London, UK) (20’)
The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the MIR-221&222-C-FOS pathway. M.C. Errico, F. Felicetti, L. Bottero, G. Mattia, N. Felli, M. Petrini, M. Bellengh, H.S. Pandha, R. Morgan, A. Carè(Rome, Italy; Guilford, UK) (20’)
HOX gene expression in ovarian cancer. A. Michael, Z.L. Kelly, C.S. Moller-Levet, H. Pandha, R. Morgan (Guildford,UK) (20’)
Closing remarks : R. Morgan(5’)

24. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION

ROOM A, 16.30-19.45 – Tuesday, October 7

Chair Persons: T.G. Cotter, R. Todorova

Oncogene driven redox survival signalling in tumour cells. T.G. Cotter, J. Stanicka, W. Laundry (Cork, Ireland) (30’)
Functional domains and IPD targeted therapy for Ewing’s sarcoma. R. Todorova (Sofia, Bulgaria) (30’)
The oxidative stress-associated SRC activator and C-SRC tyrosine kinase- novel targets in the mechanism of photodynamic therapy. M. Wozniak, K. Dus-Szachniewicz, B. Ziólkowska, P. Ziólkowski (Wroclaw, Poland) (10’)
Identification and targeting pathways involved in the development of Merlin-deficient tumours. S. Ammoun, L. Provenzano, L. Zhou, M.C. Schmid, C.O Hanemann (Plymouth, Devon, UK) (40’)
Thioredoxin reductases 1: A key member in metabolism newly identified as prognostic and targetable in non-small cell lung cancer (NSCLC). Y. Zhang, M. Zhou, H. Zeng, W. Jiang, Y. Li, W. Ma, Y. Qiu, R. Guan, C. Zhou, L. Zeng, L. Liu, Y. Xiong, N. Yang (Changsha; Beijing, China PR) (10’)
Gastric cancer in Morocco: Novel therapeutic targets. H. Amrani Hassani Joutei, N. Marchoudi, W. Mahfoud, I. Sadaoui, H. Lebrazi, T. Fechtali, H. Benomar (Casablanca; Mohammedia, Morocco) (30’)

25. SERUM MARKERS IN DIAGNOSIS AND THERAPY
ISOBM. Special Symposium Organized by R. Molina and V. Barak

ROOM B, 8.00-10.00 – Tuesday, October 7

Chair Persons: R. Klapdor, R. Molina, V. Barak

Comparison of 3 different immunoassays for determination of CA 19-9 in pancreatic cancer patients – a new aspect of potentially clinical relevance. R. Klapdor, M. Bahlo (Hamburg, Germany) (20’)
Tumor markers in lung cancer, a tool for early diagnosis? R. Molina, R.M. Marrades, J.M. Augé, J.M. Escudero, N. Viñolas, N. Reguart, J. Ramirez, X. Filella, L. Molins, A. Agusti (Barcelona,Spain) (30’)
Prognostic significance of tumor markers in breast cancer. V. Barak, B. Uziely, A. Hubert, I. Kalichman, R. Einarsson, T. Peretz (Jerusalem, Israel) (30’)
Liquid biopsy – new perspectives for prediction and monitoring of therapy response in cancer patients. S. Holdenrieder (Bonn, Germany) (30’)

26. SERUM MARKERS IN DIAGNOSIS AND THERAPY

ROOM B, 10.10-12.00 – Tuesday, October 7

Chair Persons: R. Klapdor, S. Holdenrieder, V. Barak

Biomarkers for malignant melanoma –treatment response assessment and metastasis prediction. V. Barak, S. Frenkel, S. Merims, M. Lotem, T. Peretz, I. Kalichman, J. Pe’er (Jerusalem, Israel) (30′)
Histone modifications in circulating nucleosomes as potential new biomarkers in cancer. U. Gezer, E.E. Yörüker, M. Keskin, S. Holdenrieder, N. Dalay (Istanbul, Turkey) (15’)
Roles of caveolin-1 and cyclooxygenase 2 in kidney, ureter, bladder and prostate cancers. W.-S. Chang, C.-W. Tsai, C.-M. Hsu, D.-T. Bau (Taichung, Taiwan) (15’)
Practical experience of the fecal hemoglobin immunochemical test in a colorectal cancer screening program. J.M. Auge (Barcelona, Spain) (30’)
Determination of neopterin, kynurenine and tryptophan as immune system activation markers in various biological fluids. L. Kujovská Krcmová, B. Cervinková, D. Solichová, B. Melichar, L. Sobotka, P. Solich (Králové, Czech Republic) (15’)

27. SERUM MARKERS IN DIAGNOSIS AND THERAPY

ROOM B, 13.00-15.00 – Tuesday, October 7

Chair Persons: K.J. Syrjänen, O. Topolcan

A non-invasive diagnosis of gastric cancer (GC) precursors (Helicobacter pylori infection and atrophic gastritis) by an ELISA-test (GastroPanel®) measuring 4 stomach-specific biomarkers in the blood. K.J. Syrjänen (Barretos-SP, Brazil) (40’)
Prognostic value of tumor markers in malignant melanoma. O. Topolcan, I. Treskova, J. Windrichova, V. Treska, J. Kinkorova, R. Kucera and T. Kydlicek (Plzen, Czech Republic) (15’)
Horizon 2020. J. Kinkorová (Pilsen, Czech Republic) (10’)
The clinical significance of acute phase proteins levels in non small cell lung cancers. N. Tsoukalas, C. Giaginis, M. Tolia, M. Kyriakou, I. Kostakis, E. Bournakis, A. Papakostidi, K. Ballasis, S. Theocharis, C. Chrystophyllakis, K. Liaskonis (Athens, Greece) (10’)
Cytokine profiles of benign and malignant thyroid disease. X. Provatopoulou, D. Georgiadou, E. Kalogera, G. Georgiou, T.N. Sergentanis, G.N. Zografos, A. Gounaris (Athens, Greece) (10’)

28. IMAGE-GUIDED RADIOTHERAPY
Special Symposium of the International Geriatric Radiotherapy Group (IGRG)
Organized by N.P. Nguyen

ROOM B, 15.15-19.00 – Tuesday, October 7

Chair persons: N.P. Nguyen, U. Karlsson

Elderly and cancer care. U. Karlsson (Marshfield, WI, USA)(40’)
The role of image-guided radiotherapy in dose escalation for locally advanced non-small cell lung cancer. A. Chi, N.P. Nguyen (Morgantown, WV, USA) (30’)
Treatment planning comparison between HDR & IMRT for early stage breast cancer using SAVI technique. S.R. Bose, N.P. Nguyen (Washington, DC, USA) (30’)
The potential of image-guided radiotherapy for normal organs sparing in patients with locally advanced head and neck cancer. N.P Nguyen, A. Chi, V. Vinh-Hung, O. Gorobets, S. Bose, U. Karlsson (Washington, DC, USA) (25’)
Feasibility of image-guided radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. N.P. Nguyen, S. Kratz, A. Chi, J. Vock, P. Vos, W. Shen, V. Vinh-Hung, L. Ewell, S. Jang, G. Altdorfer, U. Karlsson, J. Godinez, W. Woods, S. Dutta, F. Ampil (Washington, DC; Tucson, AZ; Morgantown; Parkersburg, WV; Greenville, NC; Marshfield, WI; Jacksonville, FL; Salisbury, MD; Shreveport, LA; San Antonio, TX, USA; Martinique, France; Lindenhofspital, Switzerland) (25’)
Studies on human cells irradiated with two radiation modalities (IMRT or conventional RT) show different molecular and cellular responses: public health implications. F.E. Ahmed, P.W. Vos, R.R. Allison, C. Jeffries (Greenville; Chapel Hill, NC, USA) (30’)

29. EXPERIMENTAL CHEMOTHERAPY

ROOM C, 08.00-12.15 – Tuesday, October 7

Chair Persons: G. Ciarimboli, J. Haybaeck

Organic cation transporters mediate cisplatin and oxaliplatin side effects. G. Ciarimboli, J. Sprowl, A. Hucke, A. Zehnhoff-Dinnesen, A. Sparreboom, E. Schlatter(Münster, Germany; Memphis, TN, USA) (30’)
Pitfalls of mouse cancer models (know your mouse). K. Helke (Charleston, SC, USA) (30’)
Intergrative oncology: Use of natural substances in oncology treatment: Useful,possible, valid. M. Bonucci (Rome, Italy) (40’)
The JAK/STAT pathway is activated in gallbladder carcinoma. E. Lederer, J. Petzold, R. Reihs, C. Ernst, K. Bettermann, R. Moriggl, M.Schlederer, L. Kenner, S. Lax, P. Obrist, Y.N. Park, K.Sik Kim, S. Flechsig, J. Hoffmann, J. Haybaeck (Graz; Vienna; Zams, Austria; Seoul, South Korea; Berlin, Germany) (30’)
Acetylcarnitine potentiates the anticarcinogenic effects of butyrate. I. Elimrani, S. Dionne, D. Saragosti, I. Qureshi, L. Levy, E. Delvin, E.G. Seidman (Montreal, Quebec, Canada) (15’)
Morphine, melatonin, marijuana, magnolia and myrrh as the “five m” schedule in the treatment of cancer pain and the possible dose-dependency of the antitumor and analgesic effects of the pineal hormone melatonin. P. Lissoni, G. Porro, G. Messina, E. Porta, F. Rovelli, M.G. Roselli, F. Brivio (Milan, Italy) (20’)
Placental alkaline phosphatase to treat tumors as well as associated weight loss and muscle wasting. Z. Kiss (Austin, MN; La Jolla, CA, USA; Budapest, Hungary) (30’)
Invitro and pH sensitive properties of calcium carbonate nanocrystal as novel delivery carrier for tamoxifen in estrogen receptor breast cancer cell line MCF-7. A.S. Kamba, A.L. Argungu, A.B.Z. Zuki (Serdang, Selangor, Malaysia) (15’)
A psychobiological approach in the treatment of advanced cancer-related pleasure deficiency. G. Messina (Milano, Italy) (20’)

30. CYTOGENETICS AND GENETICS

ROOM C, 13.00-15.30 – Tuesday, October 7

Chair Persons: D.-T. Bau, E. De Breakeleer, S. Ingvarsson

BAC analysis of chromosomal translocation breakpoints: an efficient strategy for identifying new candidate genes in malignant hemopathies. N. Douet-Guilbert, E. De Breakeleer, C. Tous, N. Gueganic, M.J. Le Bris, A. Basinko, M. De Braekeleer (Brest, France) (30’)
The genetic landscape of familial breast cancer in Iceland. S. Ingvarsson (Reykjavik, Iceland) (30’)
Identification of PRRC1-MLL, a novel fusion gene, in a case of therapy-related acute lymphoblastic leukemia. N. Douet-Guilbert, C. Meyer, J.R. Eveillerd, V. Ugo, M.J. Le Bris, A. Basinko, F. Morel, R. Marschalek, M. De Braekeleer (Brest, France; Mail, Germany) (15’)
Effects of Ataxia telangiectasia mutated (ATM) genotypes and personal smoking status on lung cancer risk in Taiwan. S.-C. Wang, W.-S. Chang, C.-M. Hsu, C.-W. Tsai, D.-T. Bau (Taichung, Taiwan, ROC) (15’)
Evaluation of the contribution of methylenetetrahydrofolate reductase genotypes to Taiwan breast cancer. C.-Y. Huang, W.-S. Chang, C.-W. Tsai, C.-M. Hsu, C.-L. Hsiao, D.-T. Bau (Taichung; Taipei, Taiwan, ROC) (10’)
The genotype/phenotype study for the role of caveolin-1 in gastrointestinal tract cancers. C. M. Hsu, W.-S. Chang, H.-X. Ji,C.-W. Tsai, D.-T. Bau (Taichung, Taiwan, ROC) (20’)

31. CARCINOGENESIS

ROOM C, 15.45-19.10 – Tuesday, October 7

Chair Persons: G.R. Rutteman, H.C.R. Wang

Reactive oxygen species-mediated breast cell carcinogenesis enhanced by chronic exposure to multiple carcinogens and intervened by dietary agents. H.C.R. Wang, L.A. Pluchino (Knoxville, Tennessee, USA) (40’)
Helicobacter pylori: Multitalented adaptation of binding properties. T. Borén (Umea, Sweden) (40’)
Molecular biological and genetic investigations of cancers in companion animals can provide important insight in (rare) cancers in the human. G.R. Rutteman (Utrecht; Wageningen, The Netherlands) (30’)
The role of the ECL cell in gastric carcinogenesis. H.L. Waldum, Ø. Hauso, Ø. Sørdal, R. Fossmark (Trondheim, Norway)(20’)
A preliminary mutagenesis study of camphor in human leukocytes culture. J.C. Santos, M.F. Bellini (Bauru, Brazil) (30’)
Silver nanoparticles increase the ionic permeability of the pleura and partially inhibit the migration of pleural mesothelial cells. V. Arsenopoulou, P.A. Molyvdas, K. Gourgoulianis, C. Hatzoglou, S.G. Zarogiannis (Larissa, Greece) (10’)

32. MICROENVIROMENTAL HETEROGENEITY OF BRAIN TUMOURS: DYNAMIC TOPOGRAPHICAL CHANGES AND ADAPTATION TO THERAPIES
Special Symposium Organized by G. Pilkington and H. Fillmore

ROOM D, 8.00-15.30 – Tuesday, October 7

Chair Persons: C. Herold-Mende, H. Fillmore, G. Pilkington

Part 1. Microenvironmental drivers of glioma heterogenecity and therapeutic resistance: Antiogenesis
Chair Person: C. Herold-Mende

Adaptive mechanisms to anti-vascular therapy. R. Bjerkvig (Bergen, Norway) (30’)
The perivascular glioma niche and its role in therapeutic resistance: safe harbour or active participant? H. Fillmore (Portsmouth, UK) (30’)

Part 2: Microenvironmental drivers of therapeutic resistance: Immune-mediated resistance
Chair Person: H. Fillmore

Contribution of the immunological microenvironment on GBM survival. C. Herold-Mende (Heidelberg, Germany)(30’)
Mesenchymal stem cells affect glioblastoma cells upon direct contact. H. Motaln, J. Schuchhard, K. Stec, B. Breznik, H. Ulrich, T.T. Lah (Sao Paulo, Brazil; Ljublijana, Slovenia) (30’)
Paradoxical role of mesenchymal stem cells in glioblastomas microenvironment. H. Motaln, J. Schuchhardt, K. Stec, B. Breznik, H. Ulrich and T.T. Lah (Potsdam; Berlin, Germany; Sao Paulo, SP, Brazil; Ljublijana, Slovenia) (20’)

Part 3. Post-doctoral and student presentations (10 min + 5 min discussion)
Chair Person: G. Pilkington

T cell target repertoire in primary and recurrent glioblastomas. C. Rapp, R. Warta, S. Stamova, P. Beckhove, M. Schnölzer, C. Herold-Mende (Heidelberg, Germany) (10’)
Mitochondrial DNA mutations and brain tumour heterogeneity: Insights from three dimensional structural analysis. K. Keatley, R.E Lloyd, Q. An, H.L. Fillmore, G. J. Pilkington, J.E. McGeehan (Portsmouth, UK) (10’)
CD15 and E-selectin mediate adhesion of non-small cell lung cancer cells to brain endothelium. S.A. Jassam, Z. Maherally, J. Smith, K. Ashkan, H.L. Fillmore and G.J. Pilkington (Portsmouth, UK) (10’)
Trick or treat: Impact of the microenvironment on the infiltration of T-cells in lower grade gliomas. S. Dettling, A. Moch, C. Geinsenberger, L. Hartmann L, A. von Deimling A, C. Herold-Mende (Heidelberg, Germany) (10’)
Deacetylation of GD3A as a potential therapeutic strategy for paediatric medulloblastoma. R. Mather, K. Stephenson, H.L. Fillmore, G.J. Pilkington (Portsmouth, UK) (10’)

Part 4. Microenvironmental impact on the cross-talk between glioma cells, immune cells and antiogenesis in glioblastoma: Potential combinational targets (Round table discussion)
Chair persons: H. Fillmore, C. Herold-Mende, R. Bjerkvig , G. Pilkington

Experimental questions/design to explore potential micro-environmental therapeutic targets; Challenges and EU collaborative proposals (ie. COST)

33. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM D, 15.45-19.10 – Tuesday, October 7

Chair persons: F. Guadagni, K. Hellstrand, J. Koch

Natural killer cell expression ofnatural cytotoxicity receptors determines relapse risk in elderly patients with acute myeloid leukemia undergoing immunotherapy with histamine dihydrochloride and interleukin-2. A. Martner, A. Rydström, R.E. Riise, J. Aurelius, M. Brune, R. Foà, K. Hellstrand, F.B. Thorén (Rome, Italy) (20′)
Histamine promotes the differentiation of dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase. A. Martner, B. Lenox, H. Grauers Wiktorin, J. Aurelius, F. Ewald, E. Aydin, F.B. Thorén, S. Hermodsson, K. Hellstrand (Gothenburg, Sweden) (30’)
The SR/CR mouse model of cancer resistance. J. Koch (Copenhagen,Denmark) (20’)
Unique activated state of U937 derived macrophage. H. Ishii, M. Ishikawa, T. Inoue, Y. Sumiya, Y. Kobayashi, H. Kouda, T. Gotoh, S. Kasutani, T. Inui, D. Kuchiike, K. Kubo, Y. Uto, T. Nishikata (Kobe; Tokushima; Osaka, Japan) (15’)
Establishment and comparison of novel assay systems for activation of macrophage using two different types of human monocytic cell line. M. Ishikawa, H. Kouda, T. Inoue, T. Inui, D. Kuchiike, K. Kubo, Y. Uto, T. Nishikata (Kobe; Tokushima; Osaka, Japan) (15’)
Interaction of uterine tumors with the immune system: implications for immunotherapy. S. Tuyaerts, A. Vanderstraeten, T. Everaert, R. Van Bree, C. Luyten, G. Verbist, F. Amant (Leuven, Belgium) (30’)
Vaccination with WT1 mRNA-electroporated dendritic cells to prevent relapse in 30 acute myeloid leukemia patients. E.L. Smits , A. Van de Velde, S. Anguille, Y. Willemen, W.A. Schroyens, A.P. Gadisseur, A. Verlinden, I. Vrelust, M. Lammens, G. Nijs, B. Stein, N. Cools, R. Malfait, M.B. Maes, K. Vermeulen, V.F. Van Tendeloo, Z.N. Berneman (Antwerp, Belgium) (30’)
Critical role of Toll-like receptors and regulatory T-cells during Helicobacter pylori-induced immunity and gastric carcinogenesis. C. Prinz, K. Kakounis, R. Mejías-Luque, R. Käbisch and M. Gerhard (Witten; Munich, Germany) (30’)

34. CHEMOPREVENTION. ENVIRONMENTAL EXPOSURE AND CANCER RISK

ROOM E, 8.00-12.00 – Tuesday, October 7

Chair Persons: W. Weber, B. Davidson

Familial cancer and prevention. W. Weber (Basel, Switzerland) (20’)
A review of risk factors in urothelial cancer. D. Curry, M. Ruddock, S. Dalleau, G. Kennedy, B. Duggan, H. O’Kane, C. Reid, K. Williamson (Belfast, UK) (20’)
Molecular backgrounds of chemoprevention: selenite, phenolics, chalcones. P. Perjési (Pecs, Hungary) (20’)
The incidence of cancer mortality in the Caribbean region from 2006 to 2012. B. Davidson (Anguilla, British West Indies) (20’)
Carotenoids and their derivatives prevent cancer by affecting the activity of diverse transcription systems. J. Levy (Beer-Sheva, Israel) (20’)
Plant-derived micronutrients inhibit estrogenic and IGF-1 activity in breast cancer cells but not in bone cells. Y. Sharoni (Beer Sheva, Israel) (20’)

35. BREAST CANCER: PATHOLOGY AND IMAGING
Special Symposium Organized by N.J. Agnantis

ROOM E, 13.00-15.00 – Tuesday, October 7

Chair Persons: N.J. Agnantis
Round Table

Discussion(10’)

Columnar cell lesions of the breast. A.C. Goussia (Ioannina, Greece) (30’)

36. CANCER STEM CELLS
Special Symposium Organized by M. Jhanwar-Uniyal, G. Sica

ROOM E, 15.15-19.00 – Tuesday, October 7

Chair Persons: G. Sica, M. Jhanwar-Uniyal

Cancer stem cells: secret and promises. G. Sica (Rome, Italy) (30’)
Mesenchymal stromal/ stem cells (MSCs) and cancer stem cells (CSCs), a tangled interrelationship with intriguing pathophysiological and clinical implications. R. Scatena, P. Bottoni, F. Iacopino, G. Sica (Rome, Italy) (40’)
Characterization of signaling pathways associated with cancer stem cells of glioblastoma multiforme. M. Jhanwar-Uniyal (New York, NY, USA) (30’)
A new way to think about tumor stem cells. J.A. Radosevich, B.T. Murphy, X. Wei, K.M. Elseth, Z.Deliu, M.Aqil, M. Bassiony (Chicago, IL, USA) (20’)
Alterations in DNA topoisomerases activity in cancer stem cells and in bacterial infected tumor cells influence the efficacy of anti-cancer agents. E. Priel, R. Peleg, R.Afriat, Y. Mizrachi-Nebentzahl, S. Horowitz (Beer-Sheva, Israel) (30’)
Proteome-based personalized anti-tumor cell therapy. A.S.Bryukhovetskiy, I.S. Bryukhovetskiy (Moscow, Russian Federation) (15’)

37. NEW INSIGHTS IN RENAL CANCER
Special Symposium of SIUrO Organized by G. Sica and G. Conti

ROOM F, 8.00-14.00 – Tuesday, October 7

Chair Persons: G. Sica, G. Martorana
Welcome address by Giario Conti, SIUrO President

Precision medicine in renal cancer: Biomarker and genomic profile studies. G.L. Pappagallo (Venice, Italy) (30’)
Genomics in translational research and targeted therapies in Renal Cancer. S.C. Jhanwar (New York, NY, USA) (30’)
Toward a new histo-pathological classification of renal tumours. G. Martignoni, D. Segala (Verona, Italy) (30’)
New methods in evaluation of VHL gene. E. Bollito, S. Vatrano, S. Cappia (Turin, Italy) (30’)
Radical nephrectomy versus partial nephrectomy in localized renal cell carcinoma. G. Martorana (Bologna, Italy) (30’)
Renal biopsy, mininvasive techniques and active surveillance in small renal tumors. A. Lapini (Florence, Italy) (30’)
The role of surgery in locally advanced or metastatic renal cell carcinoma (rcc). R. Salvioni (Milan, Italy) (30’)
First line medical therapy in advanced metastatic RCC. C. Porta, P. Giglione, F. Lombardo, C. Paglino (Pavia, Italy) (20’)

Conclusion : G. Conti

38. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM F, 14.15-16.15 – Tuesday, October 7

Chair Person: L. Amaral, G. Giamas

ATP-binding cassette (ABC) transporters are still important drug targets for combating multidrug-resistant cancer cells. G. Sgaragli (Siena, Italy) (30’)
Platinum (IV)nitroxyl complexes as possible candidates to circumvent cisplatin resistance in bladder cancer cells. M. Cetraz, V. Sen, A. Hartwig, B. Köberle, (Karlsruhe, Germany) (25’)
Nitric oxide donor-doxorubicins as MDR reversing agents. E. Gazzano, K. Chegaev, I. Pedrini , J. Kopecka, B. Rolando, R. Fruttero, S. Arpicco, D. Ghigo, C. Riganti (Torino, Italy) (20’)
Mitochondrial-targeting nitrooxy-doxorubicin: effects on P-glycoprotein and assessment of their vascular effects. M. Frosini, V. Maestrini, A. Neri, C. Santulli, C. Brizi, K. Chegaev, C. Riganti, G. Sgaragli, N.A. Colabufo, S. Saponara (Siena; Torino; Bari, Italy) (10’)
Screening for potential hazard effects from multitarget anthracycline on cardiovascular system. S. Saponara, M. Durante, M. Frosini, B. Gorelli, M. Valoti, K. Chegaev, G. Sgaragli, F. Fusi F (Siena; Torino, Italy) (10’)

39. NEW ANTICANCER AGENTS

ROOM F, 16.30-19.30 – Tuesday, October 7

Chair Persons: A. Bhushan, H.M. Warenius

Tyrosine phosphorylation: Role in antifolate resistance. A. Bhushan, T. Liu, P. Sheridan and J.C.K. Lai (Philadelphia, PA, USA) (30’)
Global anticancer targets: still a possibility? H.M. Warenius (Southampton, UK) (30’)
Brk/PTK6 as a novel therapeutic target in breast cancer. R.S. Burmi, G.A. Box, C.J. Pennington, J.A. Davies, W.J. Court, S.A. Eccles, D.R. Edwards, A. Harvey (Uxbridge, UK) (30’)
Identification and design of new C5-DNA methyltransferase inhibitors and their biological activity. P.B. Arimondo (Toulouse, France) (30’)
Exploiting the potential of lipids and frogs foams to treat Cancer. D.A. Lamprou (Glasgow, Scotland, UK) (20’)
Initial evaluation of a CD146/MUC18 targeting radioimmunoconjugate. S. Westrøm, N. Abbas, R.H. Larsen, O.S. Bruland, T.J. Jonasdottir, T.B. Bønsdorff (Oslo, Norway) (10’)